|Bid||0.325 x 0|
|Ask||0.330 x 0|
|Day's Range||0.300 - 0.330|
|52 Week Range||0.270 - 0.590|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO, May 22, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three months ended March 31, 2018. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").
TORONTO, May 3, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced the publication of their analytical evaluation of a variety of third-party over-the-counter hemp consumer products for tetrahydrocannabinol ("THC") and cannabidiol ("CBD") content to further develop its internal expertise and evaluate the consumer landscape. The publication conducted out of Delivra's research lab in Charlottetown, PEI and partially funded by Skills-PEI and by the Atlantic Canada Opportunities Agency, concluded that most third-party consumer products met the federal guidelines on THC content. As a tool, the testing method is amenable to a variety of consumer products indicating its general applicability towards cannabis oils and more complex materials like creams and edibles.
NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
TORONTO, April 26, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced that its R&D, pre-clinical and clinical teams have successfully developed and tested line-extension products using its precision topical delivery system platform, DelivraTM. With the assistance and support of Emergence, Canada's virtual incubator that supports the growth of innovative bioscience and food sector ventures, Delivra has developed its strategy and executed on ready to use products for OTC line extensions that will compliment its already existing successful LivRelief products, and is ready for the upcoming legalization of cannabis with its vast array of cannabis-related products for third party distributors for different disease indications. This acceleration of LivRelief sales growth in the topical OTC category will involve additional unique SKUs at existing accounts and an enhancement of the distribution channels, which is now over 5,200 pharmacy/grocery and natural products stores.
TORONTO, April 24, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced the ability to treat pain directly with a topical version of Advil™ (ibuprofen). In pre-clinical testing, undertaken by an independent third-party research organization, the Delivra-ibuprofen formulation provided sustained pain reduction. In the study, Delivra-ibuprofen was tested in an acute canine model of arthritis where the formulation performed equally or better for swelling and pain reduction compared its oral equivalent and test controls.
TORONTO, April 18, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced the publication of positive data from a pre-clinical study demonstrating the safety and greater bioavailability of transdermal berberine and dihydroberberine (DHB) for the prevention and treatment of cardiovascular disease related to high cholesterol and triglyceride levels. "This promising data supports Delivra's research and proprietary development of topical berberine and DHB's effectiveness to successfully reduce cholesterol and triglyceride levels. In certain cases, this treatment may provide a natural alternative to the use of statin drugs.
TORONTO , April 10, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three and twelve months ended December 31, 2017 . All ...
TORONTO, April 5, 2018 /CNW/ - Delivra Corp. (TSXV:DVA.V - News) (the "Company" or "Delivra") has completed a non-brokered private placement through the issuance of 3,561,423 units ("Units", as defined below) of the Company for gross proceeds of $1,246,498.20 (the "Offering"). Each Unit consists of one common share of the Company (a "Share") and one share purchase warrant (a "Warrant"). Each whole Warrant will entitle the holder to purchase one Share at a price of $0.50 per Share for 24 months from the date of closing, subject to the option of the Company, in the event that the closing price of Shares on the TSX Venture Exchange (the "TSXV") equals or exceeds $0.90 per Share for 10 consecutive days, to accelerate the expiry of the Warrants to 30 days after acceleration notice (the "Acceleration Option").
NEW YORK, NY / ACCESSWIRE / March 28, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
LONDON, UK / ACCESSWIRE / February 15, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Consumer-Packaged Goods industry: Maple Leaf Green ...
TORONTO, Feb. 1, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") announced today that it has signed a non-exclusive distribution agreement with NKS Health Ltd. ("NKS"), granting NKS the right to compound, distribute, promote, market and sell new unique pharmaceutical compounded product formulas developed by Delivra. The goal of the agreement is to build a partnership to both grow awareness and increase volume of sales for the Company's pharmaceutical pipeline. NKS will promote Delivra's cream-base therapeutics to physicians, hospitals and clinics in Canada through its network. Delivra has developed a suite of compounded products for pain, anxiety and diabetic foot ulcers.
TORONTO, Jan. 16, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") announced today the Company has developed a revolutionary, proprietary topical cream base therapeutic, DelivraTMN, for molecules of Cannabis, Cannabis-like and opioids, for a safer, more targeted and consistent delivery to patients afflicted with chronic pain and anxiety. "Our goal is to develop innovative products using our proprietary topical delivery platform (DelivraTM) to meet significant unmet medical needs and improve quality of life. With our proven patent-pending technology and formulation expertise, we have created medical grade products that have shown significant efficacy and predictable outcomes to patients," said Dr. Joseph Gabriele, CEO of Delivra.
LONDON, UK / ACCESSWIRE / January 12, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Consumer Packaged Goods industry: Maple Leaf Green World, ...
Delivra Corp. reported its financial results for the three and nine months ended September 30, 2017. All figures are reported in CDN dollars , unless otherwise indicated. Delivra's financial...
Delivra Corp. , announced today the appointment of Howard Lichtman to the position of Chief Marketing Officer . "Howard is a highly-experienced, accomplished business leader with a proven track......